NYSE Shariah screener · October 2026

Is Zoetis Inc. (ZTS) Halal?

PASS

Zoetis Inc. · NYSE: ZTS · Healthcare

The short answer

Yes — Zoetis Inc. (ZTS) passes this Shariah stock screen. Its business is animal health — medicines, vaccines and diagnostics for companion animals and livestock — and the FY2025 10-K discloses no haram segments (no alcohol, tobacco, gambling, conventional financial services or adult entertainment). Interest-bearing debt of $9,049M is about 31.02% of its ~$29.17B market cap ($69.10, October 2, 2026; 422,127,709 shares outstanding per the 10-K cover), below the ~33% ceiling, and interest income of $93M is about 0.98% of FY2025 revenue ($9,467M), below the 5% ceiling. Musaffa classifies ZTS as halal (October 2026); Zoya's page corroborates the filing figures; no ShariaPortfolio rating was found — reported as absent, not invented. This is a factual screen, not a religious ruling — consult a qualified scholar for personal rulings.

Gate 1 — Business activity: PASS

Zoetis Inc. (NYSE: ZTS) is a global animal-health company focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health, per its FY2025 10-K (filed 2026-02-12). It operates in two geographic segments — United States ($5,097M revenue, 54% of FY2025 total) and International ($4,254M, 45%) — plus contract manufacturing and human health products (about 1%). Roughly 300 product lines span seven major categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical and animal health diagnostics. Companion animal products were about 70% of FY2025 revenue; livestock products about 29%. Haram segments (factual, from the filing): none — Item 1 discloses no alcohol, tobacco, gambling, conventional financial services or adult entertainment activity. Gate 1 passes. Facts only.

Gate 2 — Debt and cash: PASS

Per Zoetis's FY2025 10-K (fiscal year ended December 31, 2025), interest-bearing debt was $9,049M — long-term debt $9,042M plus finance lease liabilities of $7M ($1M current, $6M non-current); the current portion of long-term debt and short-term borrowings were both zero. Against a market cap of about $29.17B ($69.10 on October 2, 2026; 422,127,709 shares outstanding per the 10-K cover), debt ÷ market cap is about 31.02%, below the ~33% ceiling — though with less headroom than most screened names. Cash and cash equivalents of $2,312M are about 7.93% of market cap. Gate 2 passes. Facts only.

Gate 3 — Non-compliant income: PASS

Zoetis's FY2025 10-K separately discloses interest income of $93M against total revenue of $9,467M — about 0.98% of revenue, well below the 5% non-compliant income ceiling. Gate 3 passes. Facts only.

Key figures used

Business: global animal health — U.S. segment $5,097M (54%), International $4,254M (45%), contract manufacturing & human health ~1%; companion animal ~70%, livestock ~29%; ~300 product lines (parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, diagnostics)
Haram segments: none — no alcohol, tobacco, gambling, conventional financial services or adult entertainment disclosed in Item 1 of the FY2025 10-K
Debt: $9,049M (long-term debt $9,042M + finance leases $7M; current portion of LTD and short-term borrowings $0) — debt ÷ market cap ≈ 31.02% of ~$29.17B, under the ~33% ceiling (tighter than most screened names)
Cash: $2,312M cash and equivalents ≈ 7.93% of market cap
Interest income: $93M vs FY2025 revenue $9,467M — ≈0.98% of revenue, under the 5% non-compliant income ceiling
Musaffa: "halal" (Oct 2026, AAOIFI methodology); Zoya: ZTS page exists and corroborates filing figures, headline rating not legible in fetched text; ShariaPortfolio: no rating found
Result: PASS on all three gates

Frequently asked questions

What does Zoetis do?

Zoetis Inc. (NYSE: ZTS), headquartered in Parsippany, New Jersey, is a global animal-health company focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health, per its FY2025 10-K (filed 2026-02-12). It operates in two geographic segments: the United States ($5,097M revenue, 54% of FY2025 total) and International ($4,254M, 45%), plus contract manufacturing and human health products (about 1%). Its portfolio of roughly 300 product lines spans seven major categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical and animal health diagnostics. Companion animal products were about 70% of FY2025 revenue and livestock products about 29%. Zoetis traces its roots to Pfizer's animal health business and has been an independent public company since 2013.

Why does Zoetis pass this Shariah stock screen?

Zoetis passes all three gates. Its business is animal health — medicines, vaccines and diagnostics — with no haram segments: the 10-K discloses no alcohol, tobacco, gambling, conventional financial services or adult entertainment activity. Interest-bearing debt of $9,049M is about 31.02% of its ~$29.17B market cap ($69.10 on October 2, 2026; 422,127,709 shares outstanding per the 10-K cover), below the ~33% ceiling, though with less headroom than most screened names. Interest income of $93M is about 0.98% of FY2025 revenue ($9,467M), below the 5% non-compliant income ceiling. Musaffa classifies ZTS as halal (October 2026, AAOIFI methodology); Zoya's page corroborates the filing figures; no ShariaPortfolio rating for ZTS was found — reported as absent, not invented. This is a factual screen, not a religious ruling — consult a qualified scholar for personal rulings.

What is Zoetis's interest-bearing debt ratio?

Per Zoetis's FY2025 10-K (fiscal year ended December 31, 2025), interest-bearing debt was $9,049M — long-term debt $9,042M plus finance lease liabilities of $7M ($1M current, $6M non-current); the current portion of long-term debt and short-term borrowings were both zero. Against a market cap of about $29.17B ($69.10 on October 2, 2026; 422,127,709 shares outstanding per the 10-K cover), debt ÷ market cap is about 31.02% — below the ~33% ceiling, though tighter than most screened names. Cash and cash equivalents of $2,312M are about 7.93% of market cap.

What is Zoetis's non-compliant income ratio?

Zoetis's FY2025 10-K separately discloses interest income of $93M against total revenue of $9,467M — about 0.98% of revenue, well below the 5% non-compliant income ceiling. Gate 3 passes. Facts only.

Do Zoya, Musaffa, or ShariaPortfolio cover Zoetis?

Musaffa covers ZTS and classifies it "halal" as of October 2026 (AAOIFI methodology, musaffa.com/stock/ZTS/). Zoya publishes a ZTS page that corroborates the FY2025 filing figures (revenue $9,467M, interest income $93M, 0.98%) but the headline rating field did not render legibly in the fetched page text, so no definitive Zoya rating is reported here. No ShariaPortfolio screening page or rating for ZTS was found — reported as absent, not invented. This page applies the screen directly from Zoetis's own filings and reports these positions honestly.

Sources

Screened 2026-10-02 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).